PATIENT ALERT: Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. CLICK HERE for more details.
CLICK HERE regarding the Change Healthcare update.

Clinical Research & Trials

USO 24014

A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Disease Types: Cellular & Gene

Available at:

Norfolk (Brock Cancer Center)

Treatment Types

Services

Support During Cancer

Cancers We Treat

Blood Cancers

Blood Disorders

Find a Provider Near You

Clinical Research & Trials

Listen to our podcast

USO 24014

A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]